Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2019.04.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.
Allergy Asthma Proc
January 2025
From the Section of Allergy, Asthma and Immunology, Medicine and Pediatrics, Pennsylvania State University School of Medicine, Hershey, Pennsylvania and.
Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. Alternative treatment options to reduce disease burden and improve quality of life are needed. To compile the evidence that supports the use of omalizumab for patients with refractory MCAS.
View Article and Find Full Text PDFEffect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.
Front Med (Lausanne)
November 2024
Faculty of Medicine, McGill University, Montreal, QC, Canada.
Background: The CIAO trial recently demonstrated a probable clinical benefit of omalizumab in the treatment of severe COVID-19; however, the mechanism underlying this benefit remains unclear. Therefore, we sought to longitudinally assess the impact of omalizumab on serum cytokines in CIAO trial patients to determine its mechanism of action.
Methods: Blood samples were collected on days 0, 2, 7, and 14 from patients recruited into the CIAO trial and who consented to this substudy.
Biomarkers for Short-Term Omalizumab Response in Chronic Spontaneous Urticaria.
Ann Dermatol
December 2024
Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Background: Omalizumab, a monoclonal antibody targeting immunoglobulin E (IgE), is approved for adults and adolescents (12 years or older) with chronic spontaneous urticaria (CSU) that does not respond to high-dose antihistamines. In Korea, there is limited research on predictive biomarkers for omalizumab response in CSU patients.
Objective: This retrospective, single-institution study aimed to identify clinical parameters predicting omalizumab response in Korean CSU patients.
Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.
Pharmaceuticals (Basel)
November 2024
Department of Pathophysiology and Transplantation, Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, 20122 Milan, Italy.
Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients' quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold.
View Article and Find Full Text PDFOmalizumab: The journey of the first anti-IgE approved for asthma and allergic disorders.
J Allergy Clin Immunol
January 2025
University of South Florida Morsani College of Medicine, Tampa, Fla. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!